2 false false false false false false false false false false true false false false false false false No description of principal activity 2025-02-01 Sage Accounts Production Advanced 2023 - FRS102_2023 234,298 234,298 234,298 xbrli:pure xbrli:shares iso4217:GBP 12392908 2025-02-01 2026-01-31 12392908 2026-01-31 12392908 2025-01-31 12392908 2024-02-01 2025-01-31 12392908 2025-01-31 12392908 2024-01-31 12392908 core:NetGoodwill 2025-02-01 2026-01-31 12392908 bus:Director1 2025-02-01 2026-01-31 12392908 core:WithinOneYear 2026-01-31 12392908 core:WithinOneYear 2025-01-31 12392908 core:ShareCapital 2026-01-31 12392908 core:ShareCapital 2025-01-31 12392908 core:RetainedEarningsAccumulatedLosses 2026-01-31 12392908 core:RetainedEarningsAccumulatedLosses 2025-01-31 12392908 core:NetGoodwill 2026-01-31 12392908 core:NetGoodwill 2025-01-31 12392908 bus:Director1 2025-01-31 12392908 bus:Director1 2026-01-31 12392908 bus:Director1 2024-01-31 12392908 bus:Director1 2025-01-31 12392908 bus:Director1 2024-02-01 2025-01-31 12392908 bus:SmallEntities 2025-02-01 2026-01-31 12392908 bus:AuditExemptWithAccountantsReport 2025-02-01 2026-01-31 12392908 bus:SmallCompaniesRegimeForAccounts 2025-02-01 2026-01-31 12392908 bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 12392908 bus:FullAccounts 2025-02-01 2026-01-31
COMPANY REGISTRATION NUMBER: 12392908

IR Interventional Radiology Limited

Filleted Unaudited Financial Statements

31 January 2026

IR Interventional Radiology Limited

Statement of Financial Position

31 January 2026

| 2026 | 2025
Note | £ | £

Fixed assets

Intangible assets | 5 | 234,298 | 234,298

Current assets

Debtors | 6 | 3,190 | 1,430
Cash at bank and in hand | 172,821 | 174,980
| --------- | ---------
| 176,011 | 176,410

Creditors: amounts falling due within one year | 7 | ( 17,918) | ( 46,249)
| --------- | ---------
Net current assets | 158,093 | 130,161
| --------- | ---------
Total assets less current liabilities | 392,391 | 364,459

Accruals and deferred income | ( 2,300) | ( 2,280)
| --------- | ---------
Net assets | 390,091 | 362,179
| --------- | ---------

Capital and reserves

Called up share capital | 100 | 100
Profit and loss account | 389,991 | 362,079
| --------- | ---------
Shareholders funds | 390,091 | 362,179
| --------- | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

IR Interventional Radiology Limited

Statement of Financial Position (continued)

31 January 2026
These financial statements were approved by the board of directors and authorised for issue on 16 March 2026 , and are signed on behalf of the board by:

Dr I Renfrew |
Director |

Company registration number: 12392908

IR Interventional Radiology Limited

Notes to the Financial Statements

Year ended 31 January 2026
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 19 Baalbec Road, Highbury, United Kingdom, N5 1QN.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Goodwill
Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight-line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 2 (2025: 2 ).
5. Intangible assets

| Goodwill
| £
Cost |
At 1 February 2025 and 31 January 2026 | 234,298
| ---------
Amortisation |
At 1 February 2025 and 31 January 2026 | –
| ---------
Carrying amount |
At 31 January 2026 | 234,298
| ---------
At 31 January 2025 | 234,298
| ---------

6. Debtors

| 2026 | 2025
| £ | £
Trade debtors | 3,190 | 1,430
| ------- | -------

7. Creditors: amounts falling due within one year

| 2026 | 2025
| £ | £
Corporation tax | 14,281 | 3,215
Other creditors | 3,637 | 43,034
| -------- | --------
| 17,918 | 46,249
| -------- | --------

8. Director's advances, credits and guarantees
During the year the director entered into the following advances and credits with the company:

| 2026
|  | Balance brought forward | Advances/ (credits) to the director | Amounts repaid | Balance outstanding
|  | £ | £ | £ | £
| Dr I Renfrew | ( 42,034) | 40,500 | ( 1,103) | ( 2,637)
|  | -------- | -------- | ------- | -------

| 2025
|  | Balance brought forward | Advances/ (credits) to the director | Amounts repaid | Balance outstanding
|  | £ | £ | £ | £
| Dr I Renfrew | ( 95,622) | 55,622 | ( 2,034) | ( 42,034)
|  | -------- | -------- | ------- | --------